Immunocore And Gadeta Announce Agreement To Develop First Gamma Delta (Γδ) Tcr Immtac For Solid Tumors

Published on December 02, 2022 12:35 PM GMT

Dec 2 (Reuters) - Immunocore Holdings PLC:

* IMMUNOCORE AND GADETA ANNOUNCE AGREEMENT TO DEVELOP FIRST GAMMA DELTA (ΓΔ) TCR IMMTAC FOR SOLID TUMORS

* IMMUNOCORE HOLDINGS PLC - CO HAS AN OPTION FOR EXCLUSIVE LICENSE TO FURTHER RESEARCH, DEVELOP AND COMMERCIALIZE IMMTAC CANDIDATES FROM COLLABORATION

* IMMUNOCORE HOLDINGS PLC - UNDER TERMS OF AGREEMENT, IMMUNOCORE AND GADETA WILL COLLABORATE ON '201 ΓΔ-TCR TARGET DISCOVERY

* IMMUNOCORE HOLDINGS- UNDER TERMS OF AGREEMENT, CO TO HAVE OPTION TO DEVELOP IMMTAC THERAPIES DERIVED FROM '201 TCR AS PART OF RESEARCH COLLABORATION Source text for Eikon: Further company coverage:

Reuters

Reuters -
96361 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.